USPTO Examiner LI RUIXIANG - Art Unit 1646

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18640824COMPOSITION COMPRISING ANTIBODY THAT BINDS TO DOMAIN II OF HER2 AND ACIDIC VARIANTS THEREOFApril 2024August 2024Allow410NoNo
18402596COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYJanuary 2024April 2024Allow410YesNo
18346437AFFINITY MOLECULES AND METHODS FOR THEIR USEJuly 2023April 2024Allow901NoNo
18323438TrkA ANTIBODY AND APPLICATION THEREOFMay 2023April 2024Allow1111NoNo
18313134TREATMENT OF INFLAMMATORY CONDITIONS BY DELIVERY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEINMay 2023October 2023Allow610NoNo
18157643ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOFJanuary 2023February 2024Allow1211NoNo
18017065IL23R BINDING MOLECULES AND METHODS OF USEJanuary 2023February 2024Allow1211NoNo
18056110STEROID ACID-PEPTIDE BASED CYTOTOXIC COMPOUNDSNovember 2022September 2023Allow1011NoNo
17932653COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYSeptember 2022October 2023Allow1311NoNo
17929458TREATMENT OF INFLAMMATORY CONDITIONS BY DELIVERY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEINSeptember 2022February 2024Allow1710NoNo
17900161ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOFAugust 2022July 2023Allow1101NoNo
17881156METHOD FOR THE PRODUCTION OF A GLYCOSYLATED IMMUNOGLOBULINAugust 2022January 2024Abandon1720NoYes
17815535COMPOSITION COMPRISING ANTIBODY THAT BINDS TO DOMAIN II OF HER2 AND ACIDIC VARIANTS THEREOFJuly 2022January 2023Allow510NoNo
17846900CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATESJune 2022April 2024Allow2221YesNo
17807801ANTI CCL24 (EOTAXIN2) ANTIBODIES FOR USE IN THE TREATMENT OF HEPATIC DISEASESJune 2022April 2024Allow2200NoNo
17836671NON-INVASIVE DIAGNOSIS OF GRAFT REJECTION IN ORGAN TRANSPLANT PATIENTSJune 2022November 2022Allow510NoNo
17824294ACTIVATABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODSMay 2022May 2024Allow2400NoNo
17739596CHIMERIC ANTIGEN RECEPTORS AGAINST MULTIPLE HLA-G ISOFORMSMay 2022July 2022Allow200NoNo
17733479COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN FELINES AND METHODS OF USEApril 2022April 2023Allow1121NoNo
17681573Bispecific antibodies binding ALK-1 and BMPR-2February 2022October 2024Abandon3110NoNo
17551147Bi-Specific Targeting Human NKG2DL and CLDN18A2 Chimeric Antigen Receptor Cells, Preparation Method and Application ThereofDecember 2021April 2022Allow401NoNo
17457142Artificial Cell Death Polypeptide For Chimeric Antigen Receptor And Uses ThereofDecember 2021March 2023Allow1611YesNo
17529927Anti-MARCO Antibodies and Uses ThereofNovember 2021July 2022Allow801NoNo
17527956TREATMENT OF INFLAMMATORY CONDITIONS BY DELIVERY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEINNovember 2021May 2022Allow610NoNo
17517559COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCERSNovember 2021June 2022Allow811NoNo
17507492PROTEIN BINDING DOMAINS STABILIZING FUNCTIONAL CONFORMATIONAL STATES OF GPCRS AND USES THEREOFOctober 2021May 2024Allow3110NoNo
17451622ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATESOctober 2021February 2024Allow2810NoNo
17499272Bifunctional Molecules for Lysosomal Targeting and Related Compositions and MethodsOctober 2021June 2023Allow2031YesNo
17484467PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATESSeptember 2021September 2023Allow2410NoNo
17471744CHIMERIC ANTIGEN RECEPTORS AGAINST MULTIPLE HLA-G ISOFORMSSeptember 2021December 2021Allow400NoNo
17469797Stable Anti-OSMR Antibody FormulationSeptember 2021September 2024Abandon3611NoNo
17466395ONCOSTATIN M RECEPTOR ANTIGEN BINDING PROTEINSSeptember 2021February 2024Allow2911NoNo
17463065METHODS FOR REDUCTION OF PATHOLOGICAL FIBROSIS AND ASSOCIATED DISORDERS AND DISEASESAugust 2021January 2024Abandon2801NoNo
17458612Specific Chimeric Antigen Receptor Cells Targeting Human CLDN18A2, Preparation Method and Application ThereofAugust 2021March 2022Allow711YesNo
17410153HUMANIZED ANTI-IL-1R3 ANTIBODIESAugust 2021February 2024Allow3011NoNo
17410129ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III CHIMERIC ANTIGEN RECEPTORS AND USE OF SAME FOR THE TREATMENT OF CANCERAugust 2021September 2023Allow2510NoNo
17407758METHOD FOR THE PRODUCTION OF A GLYCOSYLATED IMMUNOGLOBULINAugust 2021April 2022Allow820YesNo
17406400ISOFORM-SELECTIVE TGFB1 INHIBITORS AND USE THEREOFAugust 2021June 2024Allow3421YesNo
17399527METHODS OF TREATING HOMOLOGOUS RECOMBINATION DEFICIENT CANCERAugust 2021February 2024Allow3020NoNo
17397510ANTI-MET ANTIBODIES AND USES THEREOFAugust 2021October 2023Allow2610NoNo
17395676HCMV ENTRY INHIBITORSAugust 2021January 2024Abandon2910NoNo
17395331ANTI-CLAUDIN 18.2 ANTIBODIES AND USES THEREOFAugust 2021February 2024Allow3020NoNo
17392434COMPOSITIONS COMPRISING A P75 TUMOR NECROSIS FACTOR RECEPTOR/IG FUSION PROTEINAugust 2021November 2023Abandon2810NoNo
17388052COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMAJuly 2021February 2024Allow3111NoNo
17382948ROR2 ANTIBODY COMPOSITIONS AND RELATED METHODSJuly 2021July 2023Allow2401NoNo
17355839COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN FELINES AND METHODS OF USEJune 2021July 2022Allow1311NoNo
17353414Universal Immune Receptor Expressed by T Cells for the Targeting of Diverse and Multiple AntigensJune 2021October 2023Allow2810NoNo
17350608ALK7 BINDING PROTEINS AND USES THEREOFJune 2021April 2023Allow2200NoNo
17342949Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) AntibodiesJune 2021November 2023Allow2920NoNo
17342749Anti-Trkb Monoclonal Antibodies And Methods of UseJune 2021March 2024Allow3311NoNo
17342514INHIBITION OF SCUBE2, A NOVEL VEGFR2 CO-RECEPTOR, SUPPRESSES TUMOR ANGIOGENESISJune 2021September 2023Allow2711NoNo
17323917NON-INVASIVE DIAGNOSIS OF GRAFT REJECTION IN ORGAN TRANSPLANT PATIENTSMay 2021April 2022Allow1130YesNo
17302514EXPRESSION OF NOVEL CELL TAGSMay 2021June 2024Allow3731YesNo
17246005MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOFApril 2021March 2024Abandon3511NoNo
17245123ALK7:ACTRIIB HETEROMULTIMERS AND USES THEREOFApril 2021July 2023Allow2610NoNo
17243309METHOD FOR THE PRODUCTION OF A GLYCOSYLATED IMMUNOGLOBULINApril 2021August 2021Allow410YesNo
17238995COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERYApril 2021September 2023Allow2911NoNo
17233359GPCR HETEROMER INHIBITORS AND USES THEREOFApril 2021November 2023Abandon3110NoNo
17231400USE OF IL-1 BETA BINDING ANTIBODIES FOR TREATING PERIPHERAL ARTERIAL DISEASEApril 2021April 2023Abandon2410NoNo
17227017ACTIVATABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODSApril 2021February 2022Allow1011YesNo
17208409TREATMENT OF INFLAMMATORY CONDITIONS BY DELIVERY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEINMarch 2021November 2023Abandon3110NoNo
17205144DUAL RECEPTOR ANTAGONISTIC ANTIGEN-BINDING PROTEINS AND USES THEREOFMarch 2021October 2023Abandon3111NoNo
17204622USE OF IL-1 BETA BINDING ANTIBODIES TO TREAT PERIPHERAL ARTERIAL DISEASEMarch 2021March 2023Abandon2410NoNo
17196810NANOPORE BIOSENSORS FOR DETECTION OF PROTEINS AND NUCLEIC ACIDSMarch 2021May 2023Allow2620NoNo
17178926TISSUE TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTORFebruary 2021March 2024Allow3721YesNo
17177614COMPOUNDS FOR USE IN THE TREATMENT OF TELOMERE RELATED DISEASES AND/OR TELOMERE RELATED MEDICAL CONDITIONSFebruary 2021October 2023Allow3210NoNo
17176820ANTI-CLAUDIN 18.2 ANTIBODIES AND USES THEREOFFebruary 2021April 2021Allow200NoNo
17172490PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HUMAN TSLP RECEPTOR ANTIBODYFebruary 2021March 2023Allow2510NoNo
17166177ANTIBODY-DRUG CONJUGATES TARGETING uPARAPFebruary 2021July 2023Allow2921NoNo
17157810ANTI-ROR1 ANTIBODIES AND USES THEREOFJanuary 2021November 2023Allow3311NoNo
17150993IMMUNOMODULATORY FUSION PROTEINSJanuary 2021March 2024Allow3831YesNo
17130928THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND METHODS FOR USE OF SAMEDecember 2020August 2022Allow2000NoNo
17128678SINGLE-CHAIN CD137-RECEPTOR AGONIST PROTEINSDecember 2020March 2023Abandon2601NoNo
17117625METHODS FOR THE TREATMENT OF THYROID EYE DISEASEDecember 2020March 2023Abandon2710NoNo
17102112ASPGR ANTIBODIES AND USES THEREOFNovember 2020October 2023Abandon3521NoNo
16951192TGF-BETA SUPERFAMILY TYPE I AND TYPE II RECEPTOR HETEROMULTIMERS AND USES THEREOFNovember 2020October 2023Abandon3521YesNo
16950755SINGLE-CHAIN CD27-RECEPTOR AGONIST PROTEINSNovember 2020February 2023Abandon2710NoNo
17055789ANTI-HUMAN INTERLEUKIN 17A MONOCLONAL ANTIBODY AND APPLICATION THEREOFNovember 2020June 2024Allow4301NoNo
17093474RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTOR 1 (ROR1) SINGLE CHAIN FV ANTIBODY FRAGMENT CONJUGATES AND METHODS OF USE THEREOFNovember 2020August 2022Allow2100NoNo
17091552DOSING REGIMENNovember 2020July 2023Abandon3220NoNo
17052785MULTISPECIFIC BINDERS OF TGFBeta-SUPERFAMILY LIGANDS AND USES THEREOFNovember 2020May 2024Allow4221NoNo
17052425IMMUNE EFFECTOR CELL AND USE THEREOFNovember 2020May 2024Abandon4201NoNo
17049915PHARMACEUTICAL FORMULATIONS FOR NOVEL FELINE ERYTHROPOIETIN RECEPTOR AGONISTSOctober 2020February 2024Abandon4010NoNo
17077502CHIMERIC ANTIGEN RECEPTORS AGAINST MULTIPLE HLA-G ISOFORMSOctober 2020May 2021Allow711NoNo
17017238Compositions and Methods Comprising Prostate Stem Cell Antigen (PSCA) Chimeric Antigen Receptors (CARs)September 2020May 2023Allow3221NoNo
17010162ANTI-CDH6 ANTIBODY AND ANTI-CDH6 ANTIBODY-DRUG CONJUGATESeptember 2020March 2021Allow711NoNo
15733553ANTI-CLAUDIN 18.2 ANTIBODIES AND USES THEREOFAugust 2020December 2022Allow2721YesNo
16999374ANTI-GITR ANTIBODIES AND METHODS OF USE THEREOFAugust 2020September 2023Allow3721YesYes
16996265COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERYAugust 2020March 2023Allow3130NoNo
16991762ANTI-FLT-1 ANTIBODIES FOR TREATING DUCHENNE MUSCULAR DYSTROPHYAugust 2020April 2023Abandon3211NoNo
16935582COMBINATION OF ANTI-FGFR4-ANTIBODY AND BILE ACID SEQUESTRANTJuly 2020February 2023Allow3131NoNo
16962817ANTI-CLAUDIN 18.2 ANTIBODIES AND USES THEREOFJuly 2020March 2021Allow811NoNo
16928819ANTI-FLT-1 ANTIBODIES IN TREATING DUCHENNE MUSCULAR DYSTROPHYJuly 2020October 2022Abandon2701NoNo
16922734THERAPEUTIC TARGETING OF TISSUE-RESIDENT MEMORY T CELLSJuly 2020June 2024Abandon4721NoNo
16921695METHODS FOR PROMOTING PANCREATIC ISLET CELL GROWTHJuly 2020January 2024Abandon4301NoNo
16913963ANTI-GITR ANTIBODIES AND USES THEREOFJune 2020April 2022Allow2100NoNo
16956889SCREENING METHOD FOR MATERIALS THAT SUPPRESS CHARACTERISTIC BODY ODOR OF ELDERLY PEOPLEJune 2020December 2022Allow3010NoNo
16906669DETECTION OF ANALYTES USING LIVE CELLSJune 2020September 2023Allow3930NoNo
16901160FGFR3 Binding MoleculesJune 2020February 2022Allow2000NoNo
16902212METHODS OF TREATING CORONAVIRUS INFECTIONJune 2020February 2021Allow811NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LI, RUIXIANG.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
13
Examiner Affirmed
11
(84.6%)
Examiner Reversed
2
(15.4%)
Reversal Percentile
25.5%
Lower than average

What This Means

With a 15.4% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
153
Allowed After Appeal Filing
15
(9.8%)
Not Allowed After Appeal Filing
138
(90.2%)
Filing Benefit Percentile
10.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 9.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner LI, RUIXIANG - Prosecution Strategy Guide

Executive Summary

Examiner LI, RUIXIANG works in Art Unit 1646 and has examined 1,235 patent applications in our dataset. With an allowance rate of 41.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 29 months.

Allowance Patterns

Examiner LI, RUIXIANG's allowance rate of 41.9% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by LI, RUIXIANG receive 1.79 office actions before reaching final disposition. This places the examiner in the 54% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by LI, RUIXIANG is 29 months. This places the examiner in the 44% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +29.8% benefit to allowance rate for applications examined by LI, RUIXIANG. This interview benefit is in the 81% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 18.8% of applications are subsequently allowed. This success rate is in the 11% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 38.8% of cases where such amendments are filed. This entry rate is in the 51% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 40% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 77.2% of appeals filed. This is in the 65% percentile among all examiners. Of these withdrawals, 79.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 71.5% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 5.4% of allowed cases (in the 90% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 48% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.